VSTM

Verastem (VSTM) closed at $8.38 with a mean analyst price target of $15, suggesting 79% upside potential. The stock has gained 14.5% over the past four weeks.

Analysts have revised earnings estimates higher, and VSTM holds a Zacks Rank #2 (Buy) rating. However, the article cautions that price targets should not be the sole basis for investment decisions, as they are often overly optimistic.

Genmab shares rallied 10.7% following positive phase III trial data for epcoritamab in combination with R-CHOP for newly diagnosed diffuse large B-cell lymphoma. The stock's consensus EPS estimate was revised 8.7% higher over the past 30 days, though earnings are expected to decline 43.1% year-over-year while revenues grow 15.7%. The stock carries a Zacks Rank #3 (Hold) rating.